322 related articles for article (PubMed ID: 31471046)
1. Molecular Biology of Pituitary Adenomas.
Faltermeier CM; Magill ST; Blevins LS; Aghi MK
Neurosurg Clin N Am; 2019 Oct; 30(4):391-400. PubMed ID: 31471046
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors.
Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y
Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171
[TBL] [Abstract][Full Text] [Related]
3. Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.
Grzywa TM; Klicka K; Rak B; Mehlich D; Garbicz F; Zieliński G; Maksymowicz M; Sajjad E; Włodarski PK
Endocrine; 2019 Sep; 65(3):646-655. PubMed ID: 31165412
[TBL] [Abstract][Full Text] [Related]
4. Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) and guanylate kinase 1 (GUK1) are differentially expressed in GH-secreting adenomas.
da Rocha AA; Giorgi RR; de Sa SV; Correa-Giannella ML; Fortes MA; Cavaleiro AM; Machado MC; Cescato VA; Bronstein MD; Giannella-Neto D
Pituitary; 2006; 9(2):83-92. PubMed ID: 16832584
[TBL] [Abstract][Full Text] [Related]
5. Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.
Ruebel KH; Leontovich AA; Jin L; Stilling GA; Zhang H; Qian X; Nakamura N; Scheithauer BW; Kovacs K; Lloyd RV
Endocrine; 2006 Jun; 29(3):435-44. PubMed ID: 16943582
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.
Tateno T; Kato M; Tani Y; Oyama K; Yamada S; Hirata Y
Endocr J; 2009; 56(4):579-84. PubMed ID: 19318729
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptors in human pituitary tumors.
Burdman JA; Pauni M; Heredia Sereno GM; Bordón AE
Horm Metab Res; 2008 Aug; 40(8):524-7. PubMed ID: 18398784
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.
Lasolle H; Elsensohn MH; Wierinckx A; Alix E; Bonnefille C; Vasiljevic A; Cortet C; Decoudier B; Sturm N; Gaillard S; Ferrière A; Roy P; Jouanneau E; Bertolino P; Bardel C; Sanlaville D; Raverot G
Acta Neuropathol Commun; 2020 Nov; 8(1):190. PubMed ID: 33168091
[TBL] [Abstract][Full Text] [Related]
9. Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype.
Chen Y; Gao H; Xie W; Guo J; Fang Q; Zhao P; Liu C; Zhu H; Wang Z; Wang J; Gui S; Zhang Y; Li C
Aging (Albany NY); 2020 Dec; 13(1):1276-1293. PubMed ID: 33472173
[TBL] [Abstract][Full Text] [Related]
10. Neuronal differentiation and expression of neural epitopes in pituitary adenomas.
Johnson MD; Fan X; Bourne P; Walters D
J Histochem Cytochem; 2007 Dec; 55(12):1265-71. PubMed ID: 17875653
[TBL] [Abstract][Full Text] [Related]
11. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.
Buurman H; Saeger W
Eur J Endocrinol; 2006 May; 154(5):753-8. PubMed ID: 16645024
[TBL] [Abstract][Full Text] [Related]
12. A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
Casar-Borota O; Øystese KA; Sundström M; Melchior L; Popovic V
Pituitary; 2016 Aug; 19(4):407-14. PubMed ID: 27097804
[TBL] [Abstract][Full Text] [Related]
13. Dopamine D2 receptor gene expression in human adenohypophysial adenomas.
Stefaneanu L; Kovacs K; Horvath E; Buchfelder M; Fahlbusch R; Lancranjan L
Endocrine; 2001 Apr; 14(3):329-36. PubMed ID: 11444429
[TBL] [Abstract][Full Text] [Related]
14. Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients.
Cazabat L; Bouligand J; Salenave S; Bernier M; Gaillard S; Parker F; Young J; Guiochon-Mantel A; Chanson P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E663-70. PubMed ID: 22319033
[TBL] [Abstract][Full Text] [Related]
15. Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature.
Seltzer J; Ashton CE; Scotton TC; Pangal D; Carmichael JD; Zada G
Neurosurg Focus; 2015 Feb; 38(2):E17. PubMed ID: 25639319
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas.
Acunzo J; Thirion S; Roche C; Saveanu A; Gunz G; Germanetti AL; Couderc B; Cohen R; Figarella-Branger D; Dufour H; Brue T; Enjalbert A; Barlier A
Cancer Res; 2008 Dec; 68(24):10163-70. PubMed ID: 19074883
[TBL] [Abstract][Full Text] [Related]
17. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
[TBL] [Abstract][Full Text] [Related]
18. Recent clinical and pathophysiological advances in non-functioning pituitary adenomas.
Korbonits M; Carlsen E
Horm Res; 2009 Apr; 71 Suppl 2():123-30. PubMed ID: 19407508
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability analysis in pituitary adenomas.
Bujko M; Kober P; Zbijewska J; Kunicki J; Bonicki W
Neuro Endocrinol Lett; 2015; 36(5):511-4. PubMed ID: 26707053
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of survivin splice variants in pituitary tumors.
Waligórska-Stachura J; Andrusiewicz M; Sawicka-Gutaj N; Kubiczak M; Jankowska A; Liebert W; Czarnywojtek A; Waśko R; Blanco-Gangoo AR; Ruchała M
Pituitary; 2015 Jun; 18(3):410-6. PubMed ID: 25107550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
